Payment overview · 2025
General Payments
$134.17
7 reported records · 5 companies
Healthcare provider profile · identity verified
Leslie Mccrary-Etuk, MD
Allopathic & Osteopathic Physicians|Family Medicine · SAINT LOUIS, MO · NPI 1174670418
Verified facts
What the public records show
CMS Open Payments records show Leslie Mccrary-Etuk, MD received $134.17 in general payments during 2025 across 7 reported records.
Novo Nordisk Inc accounted for 39.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $52.56 | 39.2% | 3 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $24.76 | 18.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.41 | 16.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.83 | 13.3% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $17.61 | 13.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $134.17 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $52.56 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $52.56 | 3 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $24.76 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $24.76 | 1 | 2025 |
Source payment records
|
|||||
| THIRD WAVE Normalized: third wave |
Device | Hologic Sales and Service, LLC | $24.76 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.41 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.83 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.83 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $17.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 92 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 64 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
98 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
93 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
92 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
64 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 986 | 288 |
| Atorvastatin Calcium | Atorvastatin Calcium | 797 | 239 |
| Metformin Hcl | Metformin Hcl | 366 | 100 |
| Gabapentin | Gabapentin | 346 | 94 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 315 | 90 |
| Losartan Potassium | Losartan Potassium | 296 | 87 |
| Lisinopril | Lisinopril | 290 | 90 |
| Carvedilol | Carvedilol | 232 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 223 | 62 |
| Fluticasone Propionate | Fluticasone Propionate | 197 | 63 |
| Furosemide | Furosemide | 191 | 57 |
| Omeprazole | Omeprazole | 186 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 185 | 54 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 177 | 48 |
| Potassium Chloride | Potassium Chloride | 171 | 54 |
| Levothyroxine Sodium | Levothyroxine Sodium | 162 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 143 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 124 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 123 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 120 | 40 |
| Meloxicam | Meloxicam | 118 | 47 |
| Famotidine | Famotidine | 116 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 114 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 104 | 37 |
| Allopurinol | Allopurinol | 100 | 27 |
| Montelukast Sodium | Montelukast Sodium | 100 | 28 |
| Jardiance | Empagliflozin | 98 | 21 |
| Chlorthalidone | Chlorthalidone | 97 | 28 |
| Trulicity | Dulaglutide | 93 | 15 |
| Ozempic | Semaglutide | 92 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 89 | 27 |
| Eliquis | Apixaban | 88 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 84 | 24 |
| Lovastatin | Lovastatin | 82 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 82 | 37 |
| Glipizide Er | Glipizide | 80 | 19 |
| Farxiga | Dapagliflozin Propanediol | 74 | 23 |
| Oxybutynin Chloride | Oxybutynin Chloride | 73 | 22 |
| Simvastatin | Simvastatin | 73 | 18 |
| Buspirone Hcl | Buspirone Hcl | 70 | 18 |
| Trazodone Hcl | Trazodone Hcl | 70 | 22 |
| Glipizide | Glipizide | 66 | 20 |
| Levetiracetam | Levetiracetam | 65 | 19 |
| Rybelsus | Semaglutide | 64 | 16 |
| Alendronate Sodium | Alendronate Sodium | 62 | 12 |
| Nifedipine Er | Nifedipine | 62 | 17 |
| Spironolactone | Spironolactone | 61 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 61 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 56 | 21 |
| Prednisone | Prednisone | 55 | 36 |
| Metformin Hcl Er | Metformin Hcl | 54 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 51 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 18 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 47 | 38 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | 15 |
| Januvia | Sitagliptin Phosphate | 44 | suppressed |
| Baclofen | Baclofen | 43 | suppressed |
| Ezetimibe | Ezetimibe | 43 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 38 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 37 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 37 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | 16 |
| Tramadol Hcl | Tramadol Hcl | 36 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | 14 |
| Ibuprofen | Ibuprofen | 32 | 19 |
| Atenolol | Atenolol | 30 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 29 | suppressed |
| Telmisartan | Telmisartan | 29 | suppressed |
| Lidocaine | Lidocaine | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Fluconazole | Fluconazole | 27 | 14 |
| Pregabalin | Pregabalin | 27 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | 14 |
| Mupirocin | Mupirocin | 26 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 25 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Levemir Flexpen | Insulin Detemir | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 23 | 12 |
| Azithromycin | Azithromycin | 22 | 20 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 21 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 13 |
| Linzess | Linaclotide | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $134.17 · 7 records | Novo Nordisk Inc | APTIMA, Cologuard Collection Kit, Doc Band, MOUNJARO, Ozempic, Rybelsus, THINPREP 2000 PROCESSOR, THIRD WAVE, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error